Acquired crizotinib-resistant pulmonary adenocarcinoma and subsequent primary gallbladder cancer : A case report
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc..
RATIONALE: Proto-oncogene-oriented targeted therapy has limited benefits in elderly patients with multiple primary tumors.
PATIENT CONCERNS: A woman with anaplastic lymphoma kinase-positive lung adenocarcinoma developed acquired resistance after 3 years of targeted therapy with crizotinib.
DIAGNOSES: Diagnosis of unexpected subsequent primary gallbladder tumor.
INTERVENTIONS: Lenvatinib was administered therapeutically. Meanwhile, next-generation sequencing results before and after crizotinib treatment were analyzed by comparing the tumor-driving mutation genes with bioinformatics methods.
OUTCOMES: The patient died of ascites and liver failure. Furthermore, bypass activation was found to be the main reason for acquired drug resistance for this patient, and the abnormal expression of tumor suppressor genes and senescence-related genes was the likely cause of the second primary tumor.
LESSONS: A bioinformatic comparison of pre- and post-treatment sequencing in elderly oncology patients is of interest.
CONCLUSIONS: For diagnosing, precision bioinformatics analysis and repeat biopsy are equally valuable. For therapy, potential therapy such as p53 gene replacement therapy and CAR-T therapy need to be practiced for senescence-related conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Medicine - 102(2023), 11 vom: 17. März, Seite e33162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Min [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
53AH36668S |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 16.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000033162 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354354965 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354354965 | ||
| 003 | DE-627 | ||
| 005 | 20231226062035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000033162 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354354965 | ||
| 035 | |a (NLM)36930086 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acquired crizotinib-resistant pulmonary adenocarcinoma and subsequent primary gallbladder cancer |b A case report |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a RATIONALE: Proto-oncogene-oriented targeted therapy has limited benefits in elderly patients with multiple primary tumors | ||
| 520 | |a PATIENT CONCERNS: A woman with anaplastic lymphoma kinase-positive lung adenocarcinoma developed acquired resistance after 3 years of targeted therapy with crizotinib | ||
| 520 | |a DIAGNOSES: Diagnosis of unexpected subsequent primary gallbladder tumor | ||
| 520 | |a INTERVENTIONS: Lenvatinib was administered therapeutically. Meanwhile, next-generation sequencing results before and after crizotinib treatment were analyzed by comparing the tumor-driving mutation genes with bioinformatics methods | ||
| 520 | |a OUTCOMES: The patient died of ascites and liver failure. Furthermore, bypass activation was found to be the main reason for acquired drug resistance for this patient, and the abnormal expression of tumor suppressor genes and senescence-related genes was the likely cause of the second primary tumor | ||
| 520 | |a LESSONS: A bioinformatic comparison of pre- and post-treatment sequencing in elderly oncology patients is of interest | ||
| 520 | |a CONCLUSIONS: For diagnosing, precision bioinformatics analysis and repeat biopsy are equally valuable. For therapy, potential therapy such as p53 gene replacement therapy and CAR-T therapy need to be practiced for senescence-related conditions | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Crizotinib |2 NLM | |
| 650 | 7 | |a 53AH36668S |2 NLM | |
| 650 | 7 | |a Anaplastic Lymphoma Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Chen, Ruilin |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Suqun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 102(2023), 11 vom: 17. März, Seite e33162 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2023 |g number:11 |g day:17 |g month:03 |g pages:e33162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000033162 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2023 |e 11 |b 17 |c 03 |h e33162 | ||